DelveInsight Business Research LLP

DelveInsight’s ‘Pulmonary Hypertension Pipeline Insight 2023‘ report pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Pulmonary Hypertension Pipeline Report

• Over 80 + companies and 80 + pipeline drugs in Pulmonary Hypertension are in various stages of development, and their anticipated acceptance in the Pulmonary Hypertension market would significantly increase market revenue. 

• Leading Pulmonary Hypertension companies developing novel drug candidates to improve the Pulmonary Hypertension treatment landscape include Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, and many others.

• Promising Pulmonary Hypertension pipeline therapies in various stages of development include Ralinepag, Sotatercept, Zamicastat, Tocilizumab, AER-901, and many others.

Pulmonary Hypertension Overview

Pulmonary hypertension , is a complex and often misunderstood disease. The term PH means high blood pressure in the lungs. In “regular” hypertension (also known as high blood pressure or “systemic hypertension) the pressure in the arteries throughout the body is higher than it should be. This can be measured with a blood pressure cuff. In PH, the blood vessels specifically in the lungs are affected. They can become stiff, damaged or narrow, and the right side of the heart must work harder to pump blood through. Each form of PH is different, so it is important for newly-diagnosed patients to find a PH specialist who can accurately find what is causing their PH and develop a treatment plan that is right for that specific type of PH as soon as possible. Every person with PH is different, and new research is being conducted every day with the potential to improve the outlook of people living with this disease. Once in the care of a PH-treating healthcare team and on appropriate therapy, people with PH can live many years. The most common symptoms of PH can also be caused by other more common medical problems, such as asthma or chronic obstructive pulmonary disease (COPD). Therefore, diagnosing PH is difficult and requires a specialist. Physical examination signs can include visible or enlarged veins on the side of the neck, irregular heart sounds or swelling in the abdomen or legs and feet.

Pulmonary Hypertension Pipeline Analysis: Drug Profile

Ralinepag: Arena Pharmaceuticals/United Therapeutics

Ralinepag (APD811) is a next-generation, oral, selective potent, once-daily IP receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). Arena discovered and developed this drug candidate internally. Ralinepag’s potency on vasodilation, inhibition of proliferation of vascular smooth muscle cells, and inhibition of platelet aggregation, combined with an extended half-life, support its application as a potentially best-in-class agent for the treatment of PAH. Ralinepag is an investigational compound that is not approved for any use in any country.

 Sotatercept: Acceleron Pharma

Sotatercept is an investigational reverse-remodeling agent designed to be a selective ligand trap for members of the TGF-beta superfamily to rebalance signaling in the BMP pathway, which is a key molecular driver of PAH. In preclinical studies, sotatercept was shown to reverse the vascular remodeling that is a hallmark of PAH. Sotatercept is an investigational therapy that is not approved for any use in any country. Sotatercept is part of a licensing agreement with Bristol Myers Squibb.

Discover more about the emerging drugs of Pulmonary Hypertension @ Pulmonary Hypertension Treatment Drugs

Pulmonary Hypertension Pipeline Therapies and Key Companies

• Ralinepag: Arena Pharmaceuticals/United Therapeutics

• Sotatercept: Acceleron Pharma

• Zamicastat: Bial – Portela C S.A.

• Tocilizumab: Roche

• And many others.

DelveInsight’s Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 Route of Administration

Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

 Molecule Type

 Products have been categorized under various Molecule types such as

Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

 Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scope of the Pulmonary Hypertension Pipeline Report 

• Coverage: Global 

• Key Pulmonary Hypertension Companies: Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Dong-A ST/Mezzion, Northern Therapeutics

• Key Pulmonary Hypertension Pipeline Therapies: Avexitide, Dasiglucagon, HM 15136, CRN 04777, ABG 023, and others.

Find out more about the Pulmonary Hypertension treatment options in development @ Pulmonary Hypertension Clinical Trials

Table of Contents

1. Introduction of Pulmonary Hypertension

2. Executive Summary of Pulmonary Hypertension

3. Overview of Pulmonary Hypertension 

4. Pipeline Therapeutics of Pulmonary Hypertension

5. Late-Stage Products (Phase III) of Pulmonary Hypertension 

6. Mid-Stage Products (Phase II) of Pulmonary Hypertension 

7. Early Stage Products (Phase I/II) of Pulmonary Hypertension 

8. Preclinical Stage Products of Pulmonary Hypertension 

9. Discovery Stage Products of Pulmonary Hypertension 

10. Therapeutic Assessment of Pulmonary Hypertension 

11. Inactive Products of Pulmonary Hypertension 

12. Collaborations Assessment- Licensing / Partnering / Funding of Pulmonary Hypertension 

13. Unmet Needs of Pulmonary Hypertension

14. Market Drivers and Barriers of Pulmonary Hypertension

15. Appendix of Pulmonary Hypertension 

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/